688302.SHG Hinova Pharmaceuticals Inc. A

Healthcare Biotechnology Shanghai Stock Exchange
33.08 CNY
Close of Nov 4, 2026
26.53 60.00
Market cap
CNY 3.28B
P/E
-
P/B
2.92x
ROE
-11.2%
Dividend yield
0.04%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688302.SHG undervalued?

Graham number

The Graham number of Hinova Pharmaceuticals Inc. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hinova Pharmaceuticals Inc. A fundamental analysis

No fundamental analysis for Hinova Pharmaceuticals Inc. A yet.

Hinova Pharmaceuticals Inc. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hinova Pharmaceuticals Inc. A

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug…

Full company profile